Vertex Reports Third Quarter 2026 Financial Results
Business Wire•02/11/2026•16:01 ET
0
Key Highlights
- ➤Revenue $3.44 billion, up 12% year over year
- ➤FY 2026 revenue guidance raised to $13.15 billion to $13.25 billion
- ➤GAAP net income fell to $654 million from $1.1 billion
- ➤Crinetics acquisition established Vertex’s fourth commercial pillar in rare endocrine diseases
- ➤Povetacicept IgAN PDUFA target action date is November 30, 2026
Expert Statements
Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex
“Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition”
Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex
“With the potential povetacicept approval in IgAN coming later this month, we are well positioned to establish nephrology as our fifth commercial franchise and expand the reach of our transformative medicines to even more patients.”
— Achieved total revenue of $3.44 billion, a 12% increase compared to third quarter 2025 —
— Raising full-year revenue guidance to $13.15 billion to $13.25 billion —
Get started
Create a free account to read the full story.